A primer on viral-associated olfactory loss in the era of COVID-19

Zachary M Soler, Zara M Patel, Justin H Turner, Eric H Holbrook, Zachary M Soler, Zara M Patel, Justin H Turner, Eric H Holbrook

Abstract

Early reports have suggested that smell loss may be an early symptom associated with the pandemic known as coronavirus disease 2019 (COVID-19). The possibility that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might cause olfactory dysfunction is certainly plausible. Patients presenting to specialized smell clinics are commonly diagnosed with upper respiratory infection (URI)-associated olfactory loss and most are presumed to be viral related. In acute phases of infection, it is common to experience some smell loss as a result of nasal inflammation, mucosal edema, and obstruction of airflow into the olfactory cleft. In most cases, these episodes of smell loss are self-limiting and coincide with resolution of URI symptoms. However, in some cases the smell loss persists for months to years and this is presumed to occur through a more direct olfactory insult by the virus. It remains too early to know whether infection with SARS-CoV-2 causes persistent olfactory dysfunction. However, given the scale of this pandemic, if SARS-CoV-2 does cause chronic olfactory loss in even a small portion of those infected, then the overall population prevalence could be quite large. This review provides a brief, practical overview of viral-associated olfactory loss, realizing that evidence related to COVID-19 will likely not be clear for some time. Our goal is to highlight the existence and importance of this condition and provide information geared for both providers and patients. Practical suggestions regarding evaluation and treatment will be provided, realizing that there may be constraints on medical resources and the nature of this pandemic remains dynamic.

Keywords: coronavirus; olfaction; postviral; smell; upper respiratory infection.

© 2020 ARS-AAOA, LLC.

Figures

FIGURE 1
FIGURE 1
Olfactory pathway

References

    1. Bagheri SHR, Asghari AM, Farhadi M, et al. Coincidence of COVID‐19 epidemic and olfactory dysfunction outbreak. medRxiv. 2020.2003.2023.20041889. Epub 27 March 2020. 10.1101/2020.03.23.20041889.
    1. Rabin RC. Lost sense of smell may be peculiar cluse to coronavirus infection. . Epub 26 March 2020. Accessed May 14, 2020.
    1. Stone J. There's an unexpected loss of smell and taste in coronavirus patients. . Epub 20 March 2020. Accessed May 14, 2020.
    1. Bienkov A. If you've lost your sense of smell or taste, you could be a ‘hidden carrier’ of the coronavirus. . Epub 22 March 2020. Accessed May 14, 2020.
    1. Hopkins C, Kumar N. Loss of sense of smell as marker of Covid‐19 infection. . Epub 21 March 2020. Accessed May 14, 2020.
    1. Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: report of a case. Acta Neurologica Taiwanica. 2006;15:26‐28.
    1. Akerlund A, Bende M, Murphy C. Olfactory threshold and nasal mucosal changes in experimentally induced common cold. Acta Otolaryngol. 1995;115:88‐92.
    1. London B, Nabet B, Fisher AR, White B, Sammel MD, Doty RL. Predictors of prognosis in patients with olfactory disturbance. Ann Neurol. 2008;63:159‐166.
    1. Pinto JM, Wroblewski KE, Kern DW, Schumm LP, McClintock MK. Olfactory dysfunction predicts 5‐year mortality in older adults. PLoS One. 2014;9:e107541.
    1. Liu B, Luo Z, Pinto JM, et al. Relationship between poor olfaction and mortality among community‐dwelling older adults: a cohort study. Ann Intern Med. 2019;170:673‐681.
    1. Van Regemorter V, Hummel T, Rosenzweig F, Mouraux A, Rombaux P, Huart C. Mechanisms linking olfactory impairment and risk of mortality. Front Neurosci. 2020;14:140.
    1. Miwa T, Furukawa M, Tsukatani T, Costanzo RM, DiNardo LJ, Reiter ER. Impact of olfactory impairment on quality of life and disability. Arch Otolaryngol Head Neck Surg. 2001;127:497‐503.
    1. Croy I, Symmank A, Schellong J, et al. Olfaction as a marker for depression in humans. J Affect Disord. 2014;160:80‐86.
    1. Kohli P, Soler ZM, Nguyen SA, Muus JS, Schlosser RJ. The association between olfaction and depression: a systematic review. Chem Senses. 2016;41:479‐486.
    1. Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54:1‐30.
    1. Cavazzana A, Larsson M, Munch M, Hahner A, Hummel T. Postinfectious olfactory loss: a retrospective study on 791 patients. Laryngoscope. 2018;128:10‐15.
    1. Yamagishi M, Fujiwara M, Nakamura H. Olfactory mucosal findings and clinical course in patients with olfactory disorders following upper respiratory viral infection. Rhinology. 1994;32:113‐118.
    1. Holbrook EH, Leopold DA, Schwob JE. Abnormalities of axon growth in human olfactory mucosa. Laryngoscope. 2005;115:2144‐2154.
    1. Holbrook EH, Rebeiz L, Schwob JE. Office‐based olfactory mucosa biopsies. Int Forum Allergy Rhinol. 2016;6:646‐53.
    1. Schwob JE, Saha S, Youngentob SL, Jubelt B. Intranasal inoculation with the olfactory bulb line variant of mouse hepatitis virus causes extensive destruction of the olfactory bulb and accelerated turnover of neurons in the olfactory epithelium of mice. Chem Senses. 2001;26:937‐952.
    1. Brann D, Tsukahara T, Weinreb C, Logan DW, Datta SR. Non‐neuronal expression of SARS‐CoV‐2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID‐19 patients. bioRxiv 2020.03.25.009084. 10.1101/2020.03.25.009084. Epub 09 April 2020. Accessed May 14, 2020.
    1. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82:7264‐7275.
    1. Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol. 2008;63:7‐15.
    1. Harless L, Liang J. Pharmacologic treatment for postviral olfactory dysfunction: a systematic review. Int Forum Allergy Rhinol. 2016;6:760‐767.
    1. Yan CH, Overdevest JB, Patel ZM. Therapeutic use of steroids in non‐chronic rhinosinusitis olfactory dysfunction: a systematic evidence‐based review with recommendations. Int Forum Allergy Rhinol. 2019;9:165‐176.
    1. Kollndorfer K, Fischmeister FP, Kowalczyk K, et al. Olfactory training induces changes in regional functional connectivity in patients with long‐term smell loss. Neuroimage Clin. 2015;9:401‐410.
    1. Zhao H, Reed RR. X inactivation of the OCNC1 channel gene reveals a role for activity‐dependent competition in the olfactory system. Cell. 2001;104:651‐660.
    1. Watt WC, Sakano H, Lee ZY, Reusch JE, Trinh K, Storm DR. Odorant stimulation enhances survival of olfactory sensory neurons via MAPK and CREB. Neuron. 2004;41:955‐967.
    1. Hummel T, Rissom K, Reden J, Hahner A, Weidenbecher M, Huttenbrink KB. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009;119:496‐499.
    1. Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a meta‐analysis. Rhinology. 2017;55:17‐26.
    1. Damm M, Pikart LK, Reimann H, et al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. Laryngoscope. 2014;124:826‐831.
    1. Altundag A, Cayonu M, Kayabasoglu G, et al. Modified olfactory training in patients with postinfectious olfactory loss. Laryngoscope. 2015;125:1763‐1766.
    1. Pekala K, Chandra RK, Turner JH. Efficacy of olfactory training in patients with olfactory loss: a systematic review and meta‐analysis. Int Forum Allergy Rhinol. 2016;6:299‐307.
    1. Patel ZM, Wise SK, DelGaudio JM. Randomized controlled trial demonstrating cost‐effective method of olfactory training in clinical practice: essential oils at uncontrolled concentration. Laryngoscope Investig Otolaryngol. 2017;2:53‐56.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019‐nCoV lung injury. Lancet. 2020;395:473‐475.
    1. Centers for Disease Control and Prevention (CDC) . Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID‐19). Atlanta, GA: CDC; 2020. . Reviewed April 6, 2020. Accessed May 14, 2020.
    1. Zheng C, Wang J, Guo H, et al. Risk‐adapted treatment strategy for COVID‐19 patients. Int J Infect Dis. 2020;94:74‐77.
    1. Surviving Sepsis Campaign . COVID‐19 guidelines. . Mount Prospect, IL; Society of Critical Care Medicine; 2020. Updated March 20, 2020. Accessed May 14, 2020.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera